Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30179206 | 1.00 | BACE1 (0.53) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL30179395 | 0.90 | OPRM1 (0.46) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL20066046 | 0.90 | OPRM1 (0.46) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL23778450 | 0.87 | OPRM1 (0.48) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL30179345 | 0.84 | OPRM1 (0.46) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL30179284 | 0.84 | OPRM1 (0.43) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL20066043 | 0.84 | OPRM1 (0.46) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL20066044 | 0.84 | OPRM1 (0.43) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL23798683 | 0.82 | OPRL1 (0.59) | BACE1OPRM1OPRK1OPRL1CALCRL | |
| SCHEMBL23798701 | 0.82 | OPRM1 (0.51) | BACE1OPRM1OPRK1OPRL1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | claimed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| WO-2018069732-A1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105491-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | BACE1 927/4885OPRM1 32/4885OPRK1 112/4885 |
| US-20190202783-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
| US-20200290963-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
| US-11014880-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
| US-10259787-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
| US-10759751-B2 | Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | BACE1 1329/4885OPRM1 41/4885OPRK1 90/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | BACE1 570/4885OPRM1 27/4885OPRK1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.